特立帕肽在药物性颌骨坏死中的治疗作用

doi:10.13701/j.cnki.kqyxyj.2022.08.004

摘要/Abstract

摘要： 特立帕肽(Teriparatide, TPTD)是甲状旁腺激素(parathyroid hormone,PTH)的1~34位的人工合成多肽,具有促进骨合成代谢、免疫调节等作用,临床已成为治疗骨质疏松的常规药物,并逐渐开发用于颌骨相关疾病。其中,大量证据表明TPTD具有治疗药物相关性颌骨坏死(medication-related osteonecrosis of the jaw, MRONJ)的效应。本综述介绍TPTD治疗MRONJ的最新进展,研究其在治疗MRONJ的潜在价值。

关键词: 特立帕肽, 药物性颌骨坏死, 治疗

Abstract: Teriparatide(TPTD), a synthetic peptide corresponding to the first 34 amino acids of human parathyroid hormone (PTH), has been approved for the treatment of osteoporosis for its anabolic and immunoregulatory effects. Such effects inspired clinicians to dig its potential to rescue jaw bone related disease. Among these, an increasing number of research has shown the therapeutic effect of TPTD on medication-related osteonecrosis of the Jaw (MRONJ). However, the exact pathogenesis of TPTD for treating MRONJ remains largely unknown. This review focuses on the progress of TPTD in the management of MRONJ, investigating its potential value on clinical use.

Key words: Teriparatide, medication-related osteonecrosis of the jaw, treatment

王甲甲, 王绍义. 特立帕肽在药物性颌骨坏死中的治疗作用[J]. 口腔医学研究, 2022, 38(8): 718-721.

WANG Jiajia, WANG Shaoyi. Therapeutic Effect of TPTD on Medication-related Osteonecrosis of the Jaw[J]. Journal of Oral Science Research, 2022, 38(8): 718-721.

参考文献

[1] Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline [J]. J Clin Oncol, 2019, 37(25):2270-2290.
[2] Yuan F, Peng W, Yang C, et al. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis [J]. Int J Surg, 2019, 66:1-11.
[3] 张耀元,王林.甲状旁腺素在口腔治疗应用中的研究进展[J].口腔医学研究,2020,36(8):719-722.
[4] Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)] [J]. J Oral Maxillofac Surg, 2007, 65(3):573-580.
[5] Jung J, Yoo HY, Kim GT, et al. Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: A preliminary study [J]. J Bone Miner Res, 2017, 32(12):2445-2452.
[6] Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: A placebo-controlled, randomized trial [J]. J Clin Oncol, 2020, 38(26):2971-2980.
[7] Wang JY, Huo L, Yu RQ, et al. Skeletal site-specific response of jawbones and long bones to surgical interventions in rats treated with zoledronic acid [J]. Biomed Res Int, 2019, 2019:5138175.
[8] Kim JY, Jang HW, Kim JI, et al. Effects of pre-extraction intermittent PTH administration on extraction socket healing in bisphosphonate administered ovariectomized rats [J]. Sci Rep, 2021, 11(1):54.
[9] Zandi M, Dehghan A, Amini P, et al. Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw [J]. Clin Oral Investig, 2019, 23(11):3987-3993.
[10] Zandi M, Dehghan A, Zandipoor N, et al. Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats [J]. J Craniomaxillofac Surg, 2018, 46(3):466-472.
[11] Yu W, Su J. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice [J]. Oral Dis, 2020, 26(3):609-620.
[12] Kim JY, Park JH, Jung HD, et al. Treatment of medication-related osteonecrosis of the jaw around the dental implant with a once-weekly teriparatide: A case report and literature review [J]. J Oral Implantol, 2019, 45(5):403-407.
[13] Ohbayashi Y, Iwasaki A, Nakai F, et al. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration [J]. Osteoporos Int, 2020, 31(3):577-585.
[14] Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety [J]. Toxicol Pathol, 2002, 30(3):312-321.
[15] Gilsenan A, Midkiff K, Harris D, et al. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study [J]. J Bone Miner Res, 2021, 36(2):244-251.
[16] 刘艳云,徐宁,刘玉慧,等.PTH-FC对大鼠骨髓间充质干细胞增殖及骨向分化的影响[J].口腔医学研究,2018,34(6):614-618.
[17] Balani DH, Ono N, Kronenberg HM. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo [J]. J Clin Invest, 2017, 127(9):3327-3338.
[18] Dempster DW, Zhou H, Ruff VA, et al. Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study [J]. J Bone Miner Res, 2018, 33(4):627-633.
[19] Wein MN, Liang Y, Goransson O, et al. SIKs control osteocyte responses to parathyroid hormone [J]. Nat Commun, 2016, 7:13176.
[20] Canalis E. Management of endocrine disease: Novel anabolic treatments for osteoporosis [J]. Eur J Endocrinol, 2018, 178(2):R33-R44.
[21] Honma M, Ikebuchi Y, Suzuki H. RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target [J]. Pharmacol Ther, 2021, 218:107682.
[22] Cohen A, Kousteni S, Bisikirska B, et al. IGF-1 receptor expression on circulating osteoblast progenitor cells predicts tissue-based bone formation rate and response to teriparatide in premenopausal women with idiopathic osteoporosis [J]. J Bone Miner Res, 2017, 32(6):1267-1273.
[23] Zhu W, Xu R, Du J, et al. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw [J]. FASEB J, 2019, 33(4):5208-5219.
[24] Li M, Yu Y, Shi Y, et al. Decreased osteogenic ability of periodontal ligament stem cells leading to impaired periodontal tissue repair in BRONJ patients [J]. Stem Cells Dev, 2020, 29(3):156-168.
[25] Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis [J]. Med Oral Patol Oral Cir Bucal, 2020, 25(3):e326-e336.
[26] Peng Y, Liu Q, Xu D, et al. Inhibition of zoledronic acid derivatives with extended methylene linkers on osteoclastogenesis involve downregulation of JNK and Akt pathways [J]. Cell Biol Int, 2021, 45(5):1015-1029.
[27] Ricarte FR, Le Henaff C, Kolupaeva VG, et al. Parathyroid hormone(1-34) and its analogs differentially modulate osteoblastic Rankl expression via PKA/SIK2/SIK3 and PP1/PP2A-CRTC3 signaling [J]. J Biol Chem, 2018, 293(52):20200-20213.
[28] de Oliveira Puttini I, Gomes-Ferreira P, de Oliveira D, et al. Teriparatide improves alveolar bone modelling after tooth extraction in orchiectomized rats [J]. Arch Oral Biol, 2019, 102:147-154.
[29] Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity [J]. Cell Mol Immunol, 2018, 15(5):458-469.
[30] Renoux F, Stellato M, Haftmann C, et al. The AP1 transcription factor Fosl2 promotes systemic autoimmunity and inflammation by repressing treg development [J]. Cell Rep, 2020, 31(13):107826.
[31] Zhang Q, Atsuta I, Liu S, et al. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws [J]. Clin Cancer Res, 2013, 19(12):3176-3188.
[32] Li JY, Yu M, Tyagi AM, et al. IL-17 receptor signaling in osteoblasts/osteocytes mediates PTH-induced bone loss and enhances osteocytic RANKL production [J]. J Bone Miner Res, 2019, 34(2):349-360.
[33] Yu M, D'Amelio P, Tyagi AM, et al. Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice [J]. EMBO Rep, 2018, 19(1):156-171.